Ubs Asset Management Americas Inc Protagonist Therapeutics, Inc Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 287,911 shares of PTGX stock, worth $10.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
287,911
Previous 368,132
21.79%
Holding current value
$10.5 Million
Previous $16.5 Million
32.82%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
226KPut Options Held
218K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$215 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$209 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$200 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$153 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$121 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.78B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...